Noindex: medical sign-off pending

5-alpha-reductase inhibitor comparison

Finasteride and dutasteride share a treatment class, but they are not identical.

Both are used in BPH management where prostate enlargement makes 5-alpha-reductase inhibition relevant. The decision should account for labeling, enzyme coverage, adverse effects, half-life, PSA interpretation and prescriber experience.

Direct answer: Finasteride inhibits type II 5-alpha reductase; dutasteride inhibits type I and type II. Both reduce DHT, work over a longer time horizon and can lower PSA substantially. The broader enzyme inhibition does not by itself prove that dutasteride is clinically better for every patient.

FactorFinasterideDutasteride
5-alpha-reductase actionPrimarily type II inhibitionType I and type II inhibition
BPH roleUsed for symptomatic BPH with enlarged prostate; labeling also includes combination information.Used for symptomatic BPH with enlarged prostate; labeling includes monotherapy and combination with tamsulosin.
Time horizonMonths, not a rapid symptom-relief drugMonths, not a rapid symptom-relief drug
PSASubstantial suppression affects interpretationSubstantial suppression affects interpretation
Sexual adverse effectsLibido, erection and ejaculation effects appear in labelingLibido, erection and ejaculation effects appear in labeling
Persistence after stoppingShorter pharmacokinetic persistence than dutasterideLong terminal half-life means exposure can persist after discontinuation

Enzyme coverage is not a standalone verdict

Dutasteride suppresses both type I and type II isoenzymes, while finasteride is more selective for type II. That pharmacology is relevant, but a buyer should not translate “dual” into “twice as effective” or “stronger is always better.” Clinical outcomes, adverse effects, prostate size, comorbidities, preference and local formulary all matter.

Both require a long-term frame

Neither is the same kind of rapid symptom-focused choice as an alpha blocker. A person judging either after a few days may be using the wrong time horizon. Clinicians may combine a 5-ARI with an alpha blocker in selected patients when both symptom relief and progression-related goals are relevant.

PSA interpretation must travel with the prescription

Both medicines can lower PSA. The prescriber and any clinician interpreting subsequent tests need the drug name, duration and baseline or prior values. A rising PSA from the lowest value may warrant evaluation even when the absolute number does not look high. Do not apply a universal adjustment formula without clinician interpretation.

Handling and pregnancy warnings

Labeling includes warnings about exposure during pregnancy, including handling leaking or crushed capsules/tablets as applicable, because 5-ARIs can affect development of a male fetus. The exact handling language differs by product and formulation; use the current dispensed label.

Prescriber checklist

  1. Is prostate enlargement established and relevant to the treatment goal?
  2. Why is one 5-ARI preferred under the current formulary and clinical circumstances?
  3. What baseline PSA information should be recorded?
  4. When should symptoms, adverse effects and PSA be reassessed?
  5. How do half-life and persistence affect plans if adverse effects occur?
  6. Would an alpha blocker or another pathway be used concurrently, and why?

Common questions

Is dutasteride stronger?

It inhibits both enzyme types, but that does not create a universal clinical ranking.

Which works faster?

Both require a longer horizon than alpha blockers. Do not expect an immediate comparison result.

Which lowers PSA more?

Both can substantially lower PSA. Interpretation must be medication-aware rather than based on a simplistic ranking.

Which has fewer sexual side effects?

Both labels include sexual adverse effects; individual experience varies.

Can either be used without an enlarged prostate?

The BPH decision generally depends on evidence of enlargement; symptom presence alone is not the complete selection test.

Can I change from one to the other?

Only after discussing treatment goals, adverse effects and the different persistence of exposure.

Do they prevent prostate cancer?

Do not use them for that claim from this page. Their labels include important prostate-cancer-related warnings and context.

Can women handle them?

Current product-specific handling warnings must be followed, especially regarding pregnancy and damaged dosage forms.

Sources

Sources checked September 21, 2026. Medical sign-off pending.